Market capitalization | CHF2.20b |
Enterprise Value | CHF-275.81m |
PER (TTM) P/E ratio | 7.23 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | -36.73 |
P/S ratio (TTM) P/S ratio | 293.22 |
P/B ratio (TTM) P/B ratio | 0.90 |
Dividend yield | 4.98% |
Last dividend (FY23) | CHF2.00 |
As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.
1 Analyst has issued a forecast BB Biotech:
1 Analyst has issued a forecast BB Biotech:
Mar '24 |
+/-
%
|
||
Turnover | 7.51 7.51 |
183%
183%
|
|
Gross income | 1.38 1.38 |
112%
112%
|
|
EBITDA | 308 308 |
199%
199%
|
EBIT (operating result) EBIT | 308 308 |
199%
199%
|
Net profit | 308 308 |
199%
199%
|
Figures in millions CHF.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
BB Biotech AG is a closed-end investment fund, which engages in investing in biotechnology companies. It focuses on the development and commercialization of novel drugs sectors. The company was founded on November 9, 1993 and is headquartered in Schaffhausen, Switzerland.
Head office | Switzerland |
Founded | 1993 |
Website | www.bbbiotech.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.